type 2 inflammation

IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management

By MedXY 12/31/2025

A Phase 3 trial demonstrates that cendakimab significantly reduces dysphagia days and improves histologic and endoscopic markers in patients with eosinophilic esophagitis, offering a targeted therapeutic approach for this chronic type 2 inflammatory condition.

news Respiratory Specialties

Decoding COPD Heterogeneity: Airway Eosinophilia, Type 2 Inflammation, and Corticosteroid Responsiveness

By MedXY 09/19/2025

This study elucidates that airway eosinophilia in COPD is linked to enhanced type 2 inflammation in airway epithelium and predicts responsiveness to inhaled corticosteroids, revealing a distinct COPD endotype with potential for precision therapy.

Clinical Updates news Respiratory

Dupilumab Enhances Quality of Life and Relieves Respiratory Symptoms in COPD Patients with Type 2 Inflammation: Insights from BOREAS and NOTUS Trials

By MedXY 09/19/2025

Add-on dupilumab significantly improves health-related quality of life and respiratory symptoms in COPD patients with type 2 inflammation, according to pooled results from the BOREAS and NOTUS phase 3 trials.

Clinical Updates Respiratory Specialties

Type 2 Inflammation Biomarkers and Dupilumab Response in COPD: Insights from the BOREAS Phase 3 Trial

By MedXY 08/02/2025

Dupilumab significantly reduced type 2 inflammation biomarkers and exacerbation risk in COPD patients with elevated eosinophils, highlighting the value of biomarker-driven therapy.